Premium
Effect of trimepranol, a beta blocker, on plasma levels of growth hormone, insulin, glucose, and free fatty acids
Author(s) -
Nedvídková J.,
Felt V.
Publication year - 1973
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1973145881
Subject(s) - medicine , endocrinology , insulin , glucose tolerance test , plasma glucose , growth hormone , chemistry , diabetes mellitus , hormone , insulin resistance
The effect of oral administration of a new beta blocker trimepranol (1‐[3,5,6‐trimethyl‐4‐acetoxyphenoxyl‐3‐isopropylamino‐2‐propanol]) on serum levels of growth hormone (GH), immunoreactive insulin (IRI), glucose, and free fatty acids (FFA) has been studied in normal persons. Fasting levels of GH, IRI, glucose, and FFA after trimepranol were not changed. The concentration of glucose and secretory response of IRI during oral glucose tolerance test decreased after trimepranol. The insulinogenic index was not changed. The total secretory response of GH during glucose tolerance test after trimepranol was enhanced. The levels of FFA during glucose tolerance test were not changed.